Skip to content
Clinical Trials – home
Therapeutic area

Vascular disorders – page 50

  • 838 clinical trials
  • 353 recruiting
  • 378 conditions
  • 28 countries

Conditions in this area

378 conditions with trials, the busiest first

Clinical trials in Vascular disorders

838 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

838 clinical trials

Atrial fibrillation+1

Not recruiting

Study on Flecainide and Amiodarone for Treating Atrial Fibrillation in Patients with Coronary Artery Disease and Ejection Fraction Over 35%

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Flecainide Acetate
  • Sponsor:Win Medica Pharmaceutical S.A.

Study of Modified Anti-Platelet Therapy with Prasugrel, Ticagrelor, and Clopidogrel in Heart Attack Patients Undergoing Complete Revascularization

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:SORIN CRM SAS (Microport CRM)

Stress cardiomyopathy

Not recruiting

Study of Levosimendan and Glucose Monohydrate for Patients with Low Ejection Fraction Takotsubo Syndrome

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Glucose Monohydrate
  • Sponsor:Medical University Of Gdansk

Atrial fibrillation+5

Not recruiting

Study of Allopurinol to Reduce Cardiovascular Events in High-Risk Patients with Heart Disease and Long-COVID Syndrome

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Allopurinol
  • Sponsor:Agencja Badań Medycznych

Sepsis+1

Not recruiting

Study of REGN7544 for Treating Adults with Low Blood Pressure Caused by Sepsis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:REGN7544
  • Sponsor:Regeneron Pharmaceuticals Inc.

Obesity+1

Not recruiting

Study on Semaglutide for Patients with Obesity and Resistant Hypertension to Improve Blood Pressure Control

Registered drug
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Trinity College Dublin

Migraine

Not recruiting

Study on Atogepant for Preventing Menstrual Migraine in Women

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Substances:Atogepant
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on Avacopan with Rituximab or Cyclophosphamide for Children Aged 6 to 17 with Active ANCA-associated Vasculitis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Avacopan
  • Sponsor:Amgen Inc.

Cardiogenic shock

Not recruiting

Study Comparing Norepinephrine and Dobutamine for Patients with Cardiogenic Shock

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dobutamine
  • Sponsor:Azienda Unita' Sanitaria Locale Toscana Sud Est

Study of Amlenetug for Patients with Multiple System Atrophy

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:AMLENETUG
  • Sponsor:H. Lundbeck A/S

Septic shock

Not recruiting

Study on Resuscitation in Early Septic Shock Using Sodium Chloride and a Drug Combination for Patients with Septic Shock

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Potassium Chloride
  • Sponsor:Pontificia Universidad Catolica de Chile

Atrial fibrillation+1

Not recruiting

Study on Monitoring Anticoagulant Therapy with Rivaroxaban and Warfarin in Patients with Acute Coronary Syndrome and Atrial Fibrillation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rivaroxaban
  • Sponsor:Centre Hospitalier De Pau

Substances studied in this area

The therapies tested most often in Vascular disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.